Search

Displaying results 1121 - 1130 of 1786 in total
  1. Drug

    Sulfacetamide

    go.drugbank.com/drugs/DB00634
    Approved

    An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.

    Mixtures: Prascion RA, Prascion RA Cream with Sunscreens
  2. Drug

    Candesartan cilexetil

    go.drugbank.com/drugs/DB00796
    ApprovedInvestigational

    Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite,...

    Mixtures: Nra-candesartan Hctz, Nra-candesartan HctzProducts: Nra-candesartan
  3. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    It also prevents andexanet alfa from taking up space on phospholipid surface membranes, so that native FXa may bind and assemble the prothrominase complex [A35558]. … However, the effectiveness of andexanet alfa on treating bleeding related to any FXa inhibitors other than apixaban and rivaroxaban was not demonstrated, thus such use is limited [L3725].

  4. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic … [A236359] Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase

  5. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    It was approved by the FDA in December 2023 for the treatment of patients with SCD with recurrent vaso-occlusive crises. … [L49246] In January 2024, exagamglogene autotemcel received an additional FDA approval for the treatment of transfusion-dependent β-thalassemia.

  6. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    patients with congenital athymia: this marks the first and only FDA-approved treatment for such therapeutic indication. … [A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric

  7. Drug

    Fecal microbiota

    go.drugbank.com/drugs/DB17743
    ApprovedInvestigational

    [A259172] REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022. … Fecal microbiota, given either as a rectal transplant or in an oral formulation of live spores, is an FDA-approved option to prevent the recurrence of _Clostridioides difficile_ infection (CDI) in patients

  8. Drug

    Magnesium

    go.drugbank.com/drugs/DB14513
    ApprovedInvestigational

    Magnesium is classified as an alkaline earth metal and has 2 hydration shells. The element can be found in abundance in the hydrosphere and in mineral salts such as dolomite and magnesium carbonate. Common dietary sources of magnesium in...

    Mixtures: O-Cal FA multivitamin, O-Cal FA multivitaminProducts: BIOLECTRA MAGN 243 FOR ORA, BIOLECTRA MAGN 365 FOR ORA
  9. Drug

    Clenoliximab

    go.drugbank.com/drugs/DB06241
    Experimental

    Clenoliximab is a chimeric monoclonal antibody from Macaca irus against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.

  10. Drug

    Bithionol

    go.drugbank.com/drugs/DB04813
    ApprovedWithdrawn

    Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).